Primary Sclerosing CholangitisPSCRegistryNCT02736708
Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures
An observational study of Primary Sclerosing Cholangitis, run by University of Colorado, Denver at 1 site in United States.
Trial summary
Primary sclerosing cholangitis (PSC) 1. Prospectively validate interpretation criteria for the characterization of PSC strictures 2. Prospectively evaluate the accuracy of pCLE for the characterization of PSC strictures (differentiation between malignant vs. Read more about this study
- Who is it for?
- Ages 18 to 89 years
- Conditions the study is for
- Primary Sclerosing Cholangitis
- What is being tested?
- probe based confocal laser endomicroscopy
- Type of treatment
- Medical device
- How many people
- 65 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2013to May 2020
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with primary sclerosing cholangitis and a dominant stricture within the liver.
Who may be able to join
- Male or female > 18 years of age
- Clinically Indicated for ERCP and/or cholangioscopy for PSC stricture
Who cannot join
- Subjects for whom ERCP procedures are contraindicated
- Known allergy to fluorescein dye
- Presence of well-defined intrahepatic mass
- Ascending cholangitis, febrile at time of procedure
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for Primary Sclerosing Cholangitis Biliary Strictures
Primary sclerosing cholangitis (PSC)
- Prospectively validate interpretation criteria for the characterization of PSC strictures
- Prospectively evaluate the accuracy of pCLE for the characterization of PSC strictures (differentiation between malignant vs. non malignant strictures), using the newly developed interpretation criteria
- Evaluate the feasibility and safety of pCLE for the characterization of PSC strictures
Read the detailed description
pCLE (probe based confocal laser endomicroscopy) is an innovative technology, which provides real- time, microscopic imaging of tissue at the cellular level via a small diameter probe. The pCLE probe has been designed to fit into standard endoscopes and has been studied extensively in the gastrointestinal tract for real time diagnosis of conditions such as Barrett's Esophagus (BE), biliary strictures and endoscopic mucosal resection of colorectal lesions. Over 300 publications have documented the safety and efficacy of pCLE in the GI tract.
Ductal pathologies are presently diagnosed, characterized and sometimes treated during Endoscopic Retrograde CholangioPancreatography (ERCP) in which a catheter is advanced through the endoscope and inserted into the biliary or pancreatic duct, where a contrast agent is injected and X-rays are taken. But multiple tissue sampling (biopsies or brushing) requires considerable time and technical expertise with the risk of losing guide wire access across the biliary or pancreatic stricture. Tissue sampling techniques have shown to lead to highly specific results for diagnosing a malignant tumor (100%), but with low sensitivity (45- 75%). Furthermore, pancreatitis is one common and serious complication of ERCP, occurring in 5-7% of cases.
The CholangioFlex confocal miniprobe was specifically designed to explore bile and pancreatic ducts (diameter ranging from 0.9 to 2.5mm). Intended to be used via an ERCP procedure, it can be passed through the operating channel of a cholangioscope or inserted through a standard catheter.
Dr. Meining examined a small series of 14 patients with biliary strictures and Mucosal imaging was performed with a miniaturized confocal miniprobe introduced via the working channel of a cholangioscope. Thereafter, targeted biopsies were taken from the same regions. All strictures could be reached, leading to a pCLE accuracy of 86%, sensitivity of 83%, and specificity of 88%. The respective numbers for standard histopathology were 79%, 50%, and 100%.
Dr. Giovannini evaluated the diagnostic accuracy of pCLE for cholangiocarcinoma detection, on 37 patients with biliary or pancreatic strictures. The CholangioFlex confocal miniprobe was introduced in the bile or pancreatic ducts using a catheter, and strictures were imaged. Tissue sampling was then performed at the same location. In this study, the overall pCLE accuracy was 86% (vs. 53% for histology), the sensitivity and specificity of pCLE were 83% and 75% respectively compared to 65% and 53% for histology.
An observational prospective, "Cellvizio ERCP registry", was conducted which enrolled 102 patients with indeterminate or suspected biliary and/or pancreatic strictures, mass or neoplasm indicated for ERCP and/or cholangioscopy. The purpose of this multicentric trial was to compare the combination of Cellvizio with ERCP imaging to ERCP alone, using the Miami Classification (a set of image interpretation criteria developed to differentiate benign from malignant strictures). Physicians could choose whether to deliver the CholangioFlex confocal miniprobe through a cholangioscope or a catheter. Patients were followed until the physicians were able to confirm malignancy through histopathology or for a year if repeat tissue sampling led to benign results.
There were no pCLE-related adverse events in the study and 89 patients were finally evaluable, of whom 40 were proven to have cancer. The sensitivity, specificity, positive-predictive value, and negative- predictive value of pCLE for detecting cancerous strictures were 98%, 67%, 71%, and 97%, respectively,compared with 45%, 100%, 100%, and 69% for index pathology. This resulted in an overall accuracy of 81% for pCLE compared with 75% for index pathology. Accuracy for combination of ERCP and pCLE was significantly higher compared with ERCP with tissue acquisition (90% vs. 73%; P .001).
Due to the relatively low specificity, a group of investigators reviewed the false positive cases of the registry and new criteria characterizing inflammatory strictures, which are known to present pCLE features very similar to malignant strictures. 60 pCLE along with final diagnosis were reviewed by 3 pCLE-experienced gastroenterologists who refined the already existing Miami classification by devising novel pCLE criteria for the characterization of inflammatory strictures. The 4 criteria devised for diagnosing dysplasia in BE were: 1) Multiple thin white bands, 2) Dark granular pattern with scales, increased space between scales, thickened reticular structures. These criteria were then reviewed and validated in consensus by 6 pCLE experts using a set of 40 pCLE sequences. The overall accuracy was 82.5% vs. 81% for the prospective registry (n=98), resulting in a sensitivity of 81.2% (vs. 98% for the prospective study) and a specificity of 83.3% (vs. 67% for the prospective study). The corresponding interobserver agreement was fair (k=0,37). This new criteria are currently tested in a prospective multicentric trial, aiming at evaluating the impact of pCLE on the management of patient with indeterminate biliary stricture.
The purpose of the present pCLE Registry will be to study a condition with a high unmet medical need and preliminary differentiating criteria: Primary sclerosing cholangitis.
This condition offers challenges for the diagnostic pathway and could benefit from direct visualization of the tissue via a minimally invasive ductal approach.
- Conditions
- Primary Sclerosing Cholangitis
- Being tested
- probe based confocal laser endomicroscopy
- Keywords
- Primary sclerosing cholangitis
- Medical subject headings
- Cholangitis, Sclerosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
probe based confocal laser endomicroscopyDevice
Also called pCLE, Cellvizio
real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
| Study group | Role | What they receive |
|---|---|---|
| PSC | Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not Receives: Device: probe based confocal laser endomicroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity of ERCP with probe-based endomicroscopy
Sensitivity of ERCP with probe-based endomicroscopy for the differentiation between PSC and PSC-malignant stenosis.
Measured: 2 years
Differentiation between PSC and PSC-malignant stenosis
Sensitivity of ERCP with probe-based endomicroscopy for the differentiation between PSC and PSC-malignant stenosis.
Measured: 2 years
Secondary outcomes (2)
Feasibility of Technical Performance based on image quality
Technical performance based on image quality.
Measured: 2 years
Feasibility of Technical Performance based on tissue sampling accuracy
Tissue sampling accuracy based on tissue sampling accuracy.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2016 (estimated)
- Study startJan 2013
- Primary completionDec 2018
- Study completionMay 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Primary Sclerosing CholangitisStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 65 participants (actual)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Collaborators
- University of Pittsburgh, Weill Medical College of Cornell University, Northwell Health, Methodist Health System, Ochsner Health System, Mauna Kea Technologies
- Responsible party
- Sponsor
- Investigators
- Raj Shah, MD, Principal investigator, University of Colorado, Denver
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02736708
- Sponsor's protocol ID
- 12-1516
- Acronym
- PSCRegistry
- Status last verified
- Aug 2020
- First submitted
- 9 Dec 2015
- Last updated
- 26 Aug 2020
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Han S, Kahaleh M, Sharaiha RZ, Tarnasky PR, Kedia P, Slivka A, Chennat JS, Joshi V, Sejpal DV, Sethi A, Shah RJ. Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial. Gastrointest Endosc. 2021 Sep;94(3):569-576.e1. doi: 10.1016/j.gie.2021.03.027. Epub 2021 Mar 30.
PubMed 33798541
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for Primary Sclerosing Cholangitis Biliary Strictures
- ClinicalTrials.gov ID
- NCT02736708
- Acronym / sponsor ID
- PSCRegistry / 12-1516
- Conditions
- Primary Sclerosing Cholangitis
- Keywords
- Primary sclerosing cholangitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- University of Pittsburgh, Weill Medical College of Cornell University, Northwell Health, Methodist Health System, Ochsner Health System, Mauna Kea Technologies
- Study start
- Jan 2013 (actual)
- Primary completion
- Dec 2018 (actual)
- Study completion
- May 2020 (actual)
- First posted
- 13 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary sclerosing cholangitis (PSC)
- Prospectively validate interpretation criteria for the characterization of PSC strictures
- Prospectively evaluate the accuracy of pCLE for the characterization of PSC strictures (differentiation between malignant vs. non malignant strictures), using the newly developed interpretation criteria
- Evaluate the feasibility and safety of pCLE for the characterization of PSC strictures
Detailed description
pCLE (probe based confocal laser endomicroscopy) is an innovative technology, which provides real- time, microscopic imaging of tissue at the cellular level via a small diameter probe. The pCLE probe has been designed to fit into standard endoscopes and has been studied extensively in the gastrointestinal tract for real time diagnosis of conditions such as Barrett's Esophagus (BE), biliary strictures and endoscopic mucosal resection of colorectal lesions. Over 300 publications have documented the safety and efficacy of pCLE in the GI tract.
Ductal pathologies are presently diagnosed, characterized and sometimes treated during Endoscopic Retrograde CholangioPancreatography (ERCP) in which a catheter is advanced through the endoscope and inserted into the biliary or pancreatic duct, where a contrast agent is injected and X-rays are taken. But multiple tissue sampling (biopsies or brushing) requires considerable time and technical expertise with the risk of losing guide wire access across the biliary or pancreatic stricture. Tissue sampling techniques have shown to lead to highly specific results for diagnosing a malignant tumor (100%), but with low sensitivity (45- 75%). Furthermore, pancreatitis is one common and serious complication of ERCP, occurring in 5-7% of cases.
The CholangioFlex confocal miniprobe was specifically designed to explore bile and pancreatic ducts (diameter ranging from 0.9 to 2.5mm). Intended to be used via an ERCP procedure, it can be passed through the operating channel of a cholangioscope or inserted through a standard catheter.
Dr. Meining examined a small series of 14 patients with biliary strictures and Mucosal imaging was performed with a miniaturized confocal miniprobe introduced via the working channel of a cholangioscope. Thereafter, targeted biopsies were taken from the same regions. All strictures could be reached, leading to a pCLE accuracy of 86%, sensitivity of 83%, and specificity of 88%. The respective numbers for standard histopathology were 79%, 50%, and 100%.
Dr. Giovannini evaluated the diagnostic accuracy of pCLE for cholangiocarcinoma detection, on 37 patients with biliary or pancreatic strictures. The CholangioFlex confocal miniprobe was introduced in the bile or pancreatic ducts using a catheter, and strictures were imaged. Tissue sampling was then performed at the same location. In this study, the overall pCLE accuracy was 86% (vs. 53% for histology), the sensitivity and specificity of pCLE were 83% and 75% respectively compared to 65% and 53% for histology.
An observational prospective, "Cellvizio ERCP registry", was conducted which enrolled 102 patients with indeterminate or suspected biliary and/or pancreatic strictures, mass or neoplasm indicated for ERCP and/or cholangioscopy. The purpose of this multicentric trial was to compare the combination of Cellvizio with ERCP imaging to ERCP alone, using the Miami Classification (a set of image interpretation criteria developed to differentiate benign from malignant strictures). Physicians could choose whether to deliver the CholangioFlex confocal miniprobe through a cholangioscope or a catheter. Patients were followed until the physicians were able to confirm malignancy through histopathology or for a year if repeat tissue sampling led to benign results.
There were no pCLE-related adverse events in the study and 89 patients were finally evaluable, of whom 40 were proven to have cancer. The sensitivity, specificity, positive-predictive value, and negative- predictive value of pCLE for detecting cancerous strictures were 98%, 67%, 71%, and 97%, respectively,compared with 45%, 100%, 100%, and 69% for index pathology. This resulted in an overall accuracy of 81% for pCLE compared with 75% for index pathology. Accuracy for combination of ERCP and pCLE was significantly higher compared with ERCP with tissue acquisition (90% vs. 73%; P .001).
Due to the relatively low specificity, a group of investigators reviewed the false positive cases of the registry and new criteria characterizing inflammatory strictures, which are known to present pCLE features very similar to malignant strictures. 60 pCLE along with final diagnosis were reviewed by 3 pCLE-experienced gastroenterologists who refined the already existing Miami classification by devising novel pCLE criteria for the characterization of inflammatory strictures. The 4 criteria devised for diagnosing dysplasia in BE were: 1) Multiple thin white bands, 2) Dark granular pattern with scales, increased space between scales, thickened reticular structures. These criteria were then reviewed and validated in consensus by 6 pCLE experts using a set of 40 pCLE sequences. The overall accuracy was 82.5% vs. 81% for the prospective registry (n=98), resulting in a sensitivity of 81.2% (vs. 98% for the prospective study) and a specificity of 83.3% (vs. 67% for the prospective study). The corresponding interobserver agreement was fair (k=0,37). This new criteria are currently tested in a prospective multicentric trial, aiming at evaluating the impact of pCLE on the management of patient with indeterminate biliary stricture.
The purpose of the present pCLE Registry will be to study a condition with a high unmet medical need and preliminary differentiating criteria: Primary sclerosing cholangitis.
This condition offers challenges for the diagnostic pathway and could benefit from direct visualization of the tissue via a minimally invasive ductal approach.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PSC | – | Device: probe based confocal laser endomicroscopyMale or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not |
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with primary sclerosing cholangitis and a dominant stricture within the liver.
Key inclusion criteria (2 listed)
- Male or female > 18 years of age
- Clinically Indicated for ERCP and/or cholangioscopy for PSC stricture
Key exclusion criteria (5 listed)
- Subjects for whom ERCP procedures are contraindicated
- Known allergy to fluorescein dye
- Presence of well-defined intrahepatic mass
- Ascending cholangitis, febrile at time of procedure
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| probe based confocal laser endomicroscopyAlso: pCLE, Cellvizioreal-time, microscopic imaging of tissue at the cellular level via a small diameter probe. | Device | PSC |
Primary outcome
Sensitivity of ERCP with probe-based endomicroscopy
Time frame: 2 years
Sensitivity of ERCP with probe-based endomicroscopy for the differentiation between PSC and PSC-malignant stenosis.
Differentiation between PSC and PSC-malignant stenosis
Time frame: 2 years
Sensitivity of ERCP with probe-based endomicroscopy for the differentiation between PSC and PSC-malignant stenosis.
2 secondary outcomes
Feasibility of Technical Performance based on image quality
Time frame: 2 years
Feasibility of Technical Performance based on tissue sampling accuracy
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2020.
- Derived from this study: PubMed 33798541Han S, Kahaleh M, Sharaiha RZ, Tarnasky PR, Kedia P, Slivka A, Chennat JS, Joshi V, Sejpal DV, Sethi A, Shah RJ. Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial. Gastrointest Endosc. 2021 Sep;94(3):569-576.e1. doi: 10.1016/j.gie.2021.03.027. Epub 2021 Mar 30.
- Individual participant dataSharing planned: No
Related trials for Primary Sclerosing Cholangitis
RecruitingObservational study
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Primary Sclerosing Cholangitis
Not yet recruitingPhase 2
FEAST and HOPE: Redox PSC Pilot Study
Primary Sclerosing Cholangitis (PSC)
RecruitingPhase 3
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Active, not recruitingPhase 2
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Primary Sclerosing Cholangitis
Active, not recruitingPhase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raj Shah, MD principal investigator
University of Colorado, Denver
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Primary Sclerosing Cholangitis, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity of ERCP with probe-based endomicroscopy (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02736708, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2020.